RHA Redensity Eye Lido; RHA Redensity Eye
Teoxane S.A. · Decision date May 12, 2026
What did the FDA approve?
FDA records P170002/S050 as a supplement to PMA P170002, with the supplement type “Panel Track”. The recorded decision is approval, dated May 12, 2026.
FDA approval order statement
Approval for RHA Redensity Eye Lido and RHA Redensity Eye for expanding the indications to include injection into the sub-dermis and supraperiosteum for the correction of moderate to severe tissue volume deficiencies in the infraorbital region in adults aged 22 years or older.
- Regulatory pathway
- PMA supplement
- Supplement type
- Panel Track
- Clinical specialty
- General, Plastic Surgery
- Decision date
- May 12, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P170002/S050
- Regulatory pathway
- PMA supplement
- Applicant
- Teoxane S.A.
- Product code
- LMH
- Decision code
- APPR
- Decision date
- May 12, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
- Applicant
- Teoxane S.A.
- Product code
- LMH
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P170002/S050 received
Application receipt date recorded by FDA.
P170002/S048 · Related supplement
RHA Dynamic Volume, RHA4
P170002/S051 · Related supplement
RHA Redensity dermal filler
P170002/S053 · Related supplement
RHA Redensity Mepi (also called RHA1 Mepi), RHA2 Mepi, RHA3 Mepi, RHA Dynamic Volume (formerly called RHA4 Mepi)
P170002/S054 · Related supplement
RHA Redensity, RHA Redensity Mepi, RHA2 and RHA2 Mepi, RHA3 and RHA3 Mepi, RHA4 and RHA Dynamic Volume
P170002/S041 · Related supplement
RHA 2, RHA 3, RHA 4
P170002/S050 · FDA decision
Panel Track
P170002/S052 · Related supplement
RHA Redensity, RHA Redensity Mepi
P170002/S055 · Related supplement
RHA Kiss Volume
P170002/S058 · Related supplement
RHA 2, RHA 3, RHA 4
P170002/S059 · Related supplement
RHA 2, RHA 3, RHA 4
Timeline entries are records held by MedtechLedger for P170002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
RHA Dynamic Volume, RHA4P170002/S048 | Teoxane S.A. | PMA supplement | Sep 18, 2025 | FDA |
RHA Redensity dermal fillerP170002/S051 | Teoxane S.A. | PMA supplement | Jan 14, 2026 | FDA |
| Teoxane S.A. | PMA supplement | Mar 31, 2026 | FDA | |
| Teoxane S.A. | PMA supplement | Apr 1, 2026 | FDA | |
RHA 2, RHA 3, RHA 4P170002/S041 | Teoxane S.A. | PMA supplement | Apr 7, 2026 | FDA |
RHA Redensity, RHA Redensity MepiP170002/S052 | Teoxane S.A. | PMA supplement | Jul 2, 2026 | FDA |
RHA Kiss VolumeP170002/S055 | Teoxane S.A. | PMA supplement | Jul 27, 2026 | FDA |
RHA 2, RHA 3, RHA 4P170002/S058 | Teoxane S.A. | PMA supplement | Aug 28, 2026 | FDA |
RHA 2, RHA 3, RHA 4P170002/S059 | Teoxane S.A. | PMA supplement | Aug 31, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Teoxane S.A.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Les Charmilles Rue De Lyon, 105, Geneva, 1203
Sources and methodology
- Original FDA record: P170002/S050
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




